Sustained-release versus immediate-release glipizide for treatment of type 2 diabetes mellitus in chinese patients: A randomized, double-blind, double-dummy, parallel-group, 12-week clinical study

Clinical Therapeutics

Volumn 28, Issue 9, 2006, Pages 1318-1326

  Hsieh, Sheng Hwu ^a   Lin, Jen Der ^a   Cheng, Hung Yu ^a   Ho, Cheng ^a   Liou, Miaw Jene ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

glipizide; immediate release; sustained release; type 2 diabetes mellitus

Indexed keywords

GLIPIZIDE; HEMOGLOBIN A1C; METFORMIN; PLACEBO; SULFONYLUREA;

ADULT; AGED; ALBUMINURIA; ARTICLE; BACKACHE; CHINESE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DIET; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG TOLERABILITY; EXTRASYSTOLE; FEMALE; GLUCOSE BLOOD LEVEL; GOUT; HUMAN; HYPERURICEMIA; HYPOGLYCEMIA; IMMEDIATE DRUG RELEASE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUSTAINED DRUG RELEASE; TACHYCARDIA; URINARY DYSFUNCTION; URINE COLOR;

ADULT; AGED; BLOOD GLUCOSE; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLIPIZIDE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; TAIWAN; TREATMENT OUTCOME;

EID: 33750035478     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.09.010     Document Type: Article

References (23)

1. Mayfield J. Diagnosis and classification of diabetes mellitus: New criteria. Am Farn Physician 58 (1998) 1355-1362
2. Mayfield J. Diagnosis and classification of diabetes mellitus: New criteria. Am Farn Physician 58 (1998) 1369-1370
3. In: Beers M.H., and Berkow R. (Eds). Diabetes mellitus. 17th ed. The Merck Manual of Diagnosis and Therapy (1999), Merck, Whitehouse Station, NJ 165-177
4. [published correction appears in Lancet. 1999;354:602]. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
5. Bell D.S. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy. Clin Ther. 26 (2004) 1714-1727
6. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 64 (2004) 1339-1358
7. Mulder H., Schopman Sr. W., and van der Lely A.J. Extrapancreatic insulin effect of glibenclamide. Eur J Clin Pharmacol. 40 (1991) 379-381
8. Eisen S.A., Miller D.K., Woodward R.S., et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 150 (1990) 1881-1884
9. Botelho R.J., and Dudfrak II R. Home assessment of adherence to long-term medication in the elderly. J Farn Pract. 35 (1992) 61-65
10. Simonson D.C., Kourides I.A., Feinglos M., et al., Glipizide Gastrointestinal Therapeutic System Study Group. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. Diabetes Care 20 (1997) 597-606
11. Kitabchi A.E., Kaminska E., Fisher J.N., et al. Comparative efficacy and potency of long-term therapy with glipizide or glyburide in patients with type 2 diabetes mellitus. Am J Med Sci. 319 (2000) 143-148
12. Foster R.H., and Plosker G.L. Glipizide. A review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus. PharmacoEconomics 18 (2000) 289-306
13. Available at:. European Agency for the Evaluation of Medicinal Products. Accessed June 30, 2003. International Conference on Harmonisation-World Health Organization. Guideline for Good Clinical Practice [EMEA Web site]. ICH Topic E6 (2002), WHO, Geneva, Switzerland. http://www.emea.eu.int
14. World Medical Association Declaration of Helsinki: Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects [WMA Web site] (1989), WMA, Ferney-Voltaire, France
15. Donihi A.C., Raval D., Saul M., et al. Prevalence and predictors of corticosteroid-related hyperglycemia in hos pitalized patients. Endocr Pract. 12 (2006) 358-362
16. Osar Z., Samanci T., Demirel G.Y., et al. Nicotinamide effects oxidative burst activity of neutrophils in pa tients with poorly controlled type 2 diabetes mellitus. Exp Diabesity Res. 5 (2004) 155-162
17. Zillich A.J., Garg J., Basu S., et al. Thiazide diuretics, potassium, and the development of diabetes: A quantitive review. Hypertension 48 (2006) 219-224
18. Chung M., Kourides I., Canovatchel W., et al. Pharmacokinetics and pharmacodynamics of extended release glipizide GITS compared with immediate-release glipizide in patients with type II diabetes mellitus. J Clin Pharmacol. 42 (2002) 651-657
19. Berelowitz M., Fischette C., Cefalu W., et al. Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediaterelease glipizide in patients with NIDDM. Diabetes Care 17 (1994) 1460-1464
20. Melander A. Oral antidiabetic drugs: An overview. Diabet Med. 13 Suppl 6 (1996) 5143-5147
21. Jonsson A., Chan J.C., Rydberg T., et al. Effects and pharmacokinetics of oral glibenclamide and glipizide in Caucasian and Chinese patients with type-2 diabetes. Eur J Clin Pharmacol. 56 (2000) 711-714
22. Jonsson A., Chan J.C., Rydberg T., et al. Pharmacodynamics and pharmacokinetics of intravenous gliben clamide in Caucasian and Chinese patients with type-2 diabetes. Eur J Clin Pharmacol. 55 (2000) 721-727
23. Marks V., and Teale J.D. Drug-induced hypoglycemia. Endocrinol Metab Clin North Am. 28 (1999) 555-577